Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery

Br J Anaesth. 2012 Nov;109(5):754-61. doi: 10.1093/bja/aes248. Epub 2012 Jul 31.

Abstract

Background: Previous studies have demonstrated beneficial immunological effects of fever-range whole-body hyperthermia (FR-WBH) as an adjunct to non-surgical cancer therapy. We conducted a study of preoperative FR-WBH in patients undergoing colorectal cancer surgery to evaluate perioperative, hyperthermia-induced immunomodulation.

Methods: The trial was conducted as a subject-blinded, controlled, randomized study. Subjects in the FR-WBH group (n=9) were treated with FR-WBH before operation under propofol sedation; the target core temperature was 39 (0.5)°C with 1 h warming and 2 h plateau phase. Subjects in the control group (n=9) were treated with propofol sedation only. Blood samples were acquired before and after treatment, after operation, and 24, 48 h, and 5 days after the end of surgery. The following parameters were measured: lipopolysaccharide (LPS)-induced tumour necrosis factor (TNF)-α, procalcitonin (PCT), interleukin (IL)-6/10, heat shock proteins (HSPs) 60, 70, and 90, human leucocyte antigen-DR (HLA-DR), and LPS-binding protein (LBP).

Results: HSPs were increased in the FR-WBH group after treatment [HSP60, 48 h postop: 143 (41)% vs 89 (42)%, P=0.04; HSP90, postop: 111 (33)% vs 64 (31)%, P=0.04; HSP70: P=0.40; FR-WBH vs control, P-values for area under the level/time curve]. TNF-α levels were elevated after surgery in the control group and remained near baseline in the FR-WBH group [24 h postop: 73 (68)% vs 151 (72)%, P=0.04]. PCT increased in both groups 24 h after surgery; in the control group, this increase was significantly higher (P=0.02). There were no significant differences for IL, HLA-DR, or LBP.

Conclusions: The immune system to react to surgical stress, as measured by a panel of laboratory indicators, might be improved by preoperative FR-WBH.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute-Phase Proteins / immunology
  • Aged
  • Biomarkers / blood
  • Calcitonin / blood
  • Calcitonin / immunology
  • Calcitonin Gene-Related Peptide
  • Carrier Proteins / blood
  • Carrier Proteins / immunology
  • Colorectal Neoplasms / blood
  • Colorectal Neoplasms / immunology
  • Colorectal Neoplasms / surgery*
  • Colorectal Surgery*
  • Female
  • Fever
  • HLA Antigens / blood
  • HLA Antigens / immunology
  • Heat-Shock Proteins / blood
  • Heat-Shock Proteins / immunology
  • Humans
  • Hyperthermia, Induced / methods*
  • Immunomodulation / immunology*
  • Interleukin-10 / blood
  • Interleukin-10 / immunology
  • Interleukin-6 / blood
  • Interleukin-6 / immunology
  • Male
  • Membrane Glycoproteins / blood
  • Membrane Glycoproteins / immunology
  • Middle Aged
  • Preoperative Care / methods*
  • Protein Precursors / blood
  • Protein Precursors / immunology
  • Single-Blind Method
  • Tumor Necrosis Factor-alpha / blood
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Acute-Phase Proteins
  • Biomarkers
  • CALCA protein, human
  • Carrier Proteins
  • HLA Antigens
  • Heat-Shock Proteins
  • Interleukin-6
  • Membrane Glycoproteins
  • Protein Precursors
  • Tumor Necrosis Factor-alpha
  • lipopolysaccharide-binding protein
  • Interleukin-10
  • Calcitonin
  • Calcitonin Gene-Related Peptide